Web Desc
Alzheimer's Disease - From Fundamental Insights to Light at the End of the Translational Tunnel
joint with Parkinson's Disease: Genetics, Mechanisms and Therapeutics
Organizer(s): John Q. Trojanowski, Charles F. Albright and Hui Zheng
Date: March 02 - 07, 2014
Location: Keystone Resort, Keystone, CO, USA
Sponsored by AstraZeneca, Genentech, Inc., Pfizer Inc., Roche and Takeda Pharmaceutical Company Limited
For important information on the coronavirus, please click here
Summary of Meeting:
Alzheimer’s disease (AD), Parkinson’s disease (PD) and related neurodegenerative disorders are becoming increasingly more prevalent in the United States and globally due to the longevity revolution. The consequences of these diseases are grave, both for individuals and the global community, prompting concerns that rising healthcare costs have the potential to result in deleterious effects on national economies that could spell disaster unless disease-modifying therapies are discovered very soon. Fortunately, remarkable progress has been made toward elucidating mechanisms of AD since the discovery of the Abeta peptide in 1984, which launched the molecular era of AD research. That, coupled with the demonstration that tau is a building block of AD tangles in 1991, led to the understanding that AD, PD and most other neurodegenerative disorders are protein misfolding diseases, which has led to further clarity about mechanisms underlying AD. This has culminated in the identification of new targets for disease-modifying therapies as well as biomarkers for AD. Most recently, provocative data have emerged suggesting that the progression of AD may be due to the cell-to-cell spread of pathological species of tau and Abeta, thereby ushering in exciting new opportunities to arrest AD progression with immune therapies. Thus, the purpose of this meeting, which will be held in concert with a parallel meeting on “Parkinson’s Disease: Genetics, Mechanisms and Therapeutics,” is to explore these fundamental insights into mechanisms of AD and the opportunities they provide to translate this knowledge into meaningful interventions for AD.
Scholarship Deadline: November 5 2013
Discounted Abstract Deadline: November 5 2013
Abstract Deadline: December 5 2013
Discounted Registration Deadline: January 8 2014
Abstacts when book is in proofing process


Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
AstraZenecaGenentech, Inc.Pfizer Inc.RocheTakeda Pharmaceutical Company Limited
We gratefully acknowledge additional support for this conference from:
Alzheimer
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Bristol-Myers Squibb Company

Merck
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Neurological Disorders and Stroke (NINDS)
Grant No. 1R13NS084618-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, March 02 | 4:00PM - 8:00PM
Arrival and Registration
Room: Longs Peak Foyer


Monday, March 03 | 7:00AM - 8:00AM
Breakfast
Room: Quandary Peak


Monday, March 03 | 8:00AM - 9:00AM
Keynote Address (Joint)
Room: Longs/Grays Peaks

Speaker 1 of 2
* John Q. Trojanowski, University of Pennsylvania, USA

Monday, March 03 | 8:00AM - 9:00AM
Keynote Address (Joint)
Room: Longs/Grays Peaks

Speaker 2 of 2
Michel Goedert, Medical Research Council, UK
Alzheimer’s Disease and Parkinson’s Disease Are Protein Misfolding Diseases

Monday, March 03 | 9:00AM - 11:30AM
Phenotypic and Genotypic Complexity of AD and PD (Joint)
Room: Longs/Grays Peaks

Speaker 1 of 5
Andrew B. Singleton, NIA, National Institutes of Health, USA
Genetics of AD and PD

Monday, March 03 | 9:00AM - 11:30AM
Phenotypic and Genotypic Complexity of AD and PD (Joint)
Room: Longs/Grays Peaks

Speaker 2 of 5
Christian C. Raiss, University of Twente, Netherlands
Short Talk: Morphological and Functional Heterogeneity of Lewy Body-Like Inclusions in a Cell Model System

Monday, March 03 | 9:00AM - 11:30AM
Phenotypic and Genotypic Complexity of AD and PD (Joint)
Room: Longs/Grays Peaks

Speaker 3 of 5
Tina L. Beckett, University of Kentucky, USA
Short Talk: Cerebrovascular Pathology and Neuroinflammatory Changes in a Novel Mouse Model of Mixed Dementia

Monday, March 03 | 9:00AM - 11:30AM
Phenotypic and Genotypic Complexity of AD and PD (Joint)
Room: Longs/Grays Peaks

Speaker 4 of 5
Dennis W. Dickson, Mayo Clinic, USA
Pathological Overlap of AD and PD

Monday, March 03 | 9:00AM - 11:30AM
Phenotypic and Genotypic Complexity of AD and PD (Joint)
Room: Longs/Grays Peaks

Speaker 5 of 5
Ryan J. Watts, Denali Therapeutics Inc, USA
Overcoming Barriers in Alzheimer’s Drug Development

Monday, March 03 | 9:40AM - 10:00AM
Coffee Break
Room: Longs Peak Foyer


Monday, March 03 | 11:30AM - 1:00PM
Poster Setup
Room: Quandary Peak


Monday, March 03 | 11:30AM - 4:30PM
On Own for Lunch and Recreation


Monday, March 03 | 1:00PM - 10:00PM
Poster Viewing
Room: Quandary Peak


Monday, March 03 | 4:00PM - 4:30PM
Coffee Available
Room: Longs Peak Foyer


Monday, March 03 | 4:30PM - 6:30PM
Genetics of AD
Room: Longs Peak

Speaker 1 of 5
* Virginia M. Y. Lee, University of Pennsylvania School of Medicine, USA

Monday, March 03 | 4:30PM - 6:30PM
Genetics of AD
Room: Longs Peak

Speaker 2 of 5
Christine Van Broeckhoven, VIB, University of Antwerp, Belgium
Genetics of Early-Onset Alzheimer Disease: What Is Missing?

Monday, March 03 | 4:30PM - 6:30PM
Genetics of AD
Room: Longs Peak

Speaker 3 of 5
Richard Mayeux, Columbia University, USA
The Search for Functional Genetic Variants in Late-Onset Alzheimer's Disease

Monday, March 03 | 4:30PM - 6:30PM
Genetics of AD
Room: Longs Peak

Speaker 4 of 5
Philip L. De Jager, Columbia University Medical Center, USA
Short Talk: Deconstructing the Epigenomic Architecture of the Cortex in Alzheimer’s Disease

Monday, March 03 | 4:30PM - 6:30PM
Genetics of AD
Room: Longs Peak

Speaker 5 of 5
Gerard D. Schellenberg, University of Pennsylvania, USA
New AD Risk Factor Genes from GWAS

Monday, March 03 | 4:30PM - 6:30PM
Genome-Wide Association and PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 1 of 5
* Andrew B. Singleton, NIA, National Institutes of Health, USA


Monday, March 03 | 4:30PM - 6:30PM
Genome-Wide Association and PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 2 of 5
Thomas Gasser, University of Tübingen, Germany
GWA Studies in PD: New Pathways and Old Targets


Monday, March 03 | 4:30PM - 6:30PM
Genome-Wide Association and PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 3 of 5
Vincent Plagnol, University College London, Genetics Institute, UK
Fine-Mapping, Gene Expression and Splicing Analysis of the Disease Associated LRRK2 Locus


Monday, March 03 | 4:30PM - 6:30PM
Genome-Wide Association and PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 4 of 5
George T. Kannarkat, Emory University School of Medicine, USA
Short Talk: The rs3129882 Single Nucleotide Polymorphism Alters MHC-II Expression and May Increase Susceptibility for Parkinson’s Disease by Modulating Immune Responses


Monday, March 03 | 4:30PM - 6:30PM
Genome-Wide Association and PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 5 of 5
Haydeh Payami, University of Alabama, Birmingham, USA
Interaction between Genes and Environment in PD


Monday, March 03 | 6:30PM - 7:30PM
Social Hour with Lite Bites
Room: Quandary Peak


Monday, March 03 | 7:30PM - 10:00PM
Poster Session 1
Room: Quandary Peak


Tuesday, March 04 | 7:00AM - 8:00AM
Breakfast
Room: Quandary Peak


Tuesday, March 04 | 8:00AM - 11:15AM
Biomarkers of AD and PD (Joint)
Room: Longs/Grays Peaks

Speaker 1 of 7
* Clifford R. Jack, Mayo Clinic, USA

Tuesday, March 04 | 8:00AM - 11:15AM
Biomarkers of AD and PD (Joint)
Room: Longs/Grays Peaks

Speaker 2 of 7
Kenneth L. Marek, Institute for Neurodegenerative Disorders, USA
Parkinson's Progression Marker Initiative:
Developing a Translational Toolbox for Parkinson's Disease


Tuesday, March 04 | 8:00AM - 11:15AM
Biomarkers of AD and PD (Joint)
Room: Longs/Grays Peaks

Speaker 3 of 7
Kaj Blennow, University of Gothenburg, Sweden
CSF Biomarkers for AD: Approaching the End of the Long Road to Validated and Approved Biomarkers

Tuesday, March 04 | 8:00AM - 11:15AM
Biomarkers of AD and PD (Joint)
Room: Longs/Grays Peaks

Speaker 4 of 7
Anna Cartier, ICB International, Inc., USA
Short Talk: A Novel Blood-Brain Barrier Permeable PET Ligand for Parkinson’s Disease

Tuesday, March 04 | 8:00AM - 11:15AM
Biomarkers of AD and PD (Joint)
Room: Longs/Grays Peaks

Speaker 5 of 7
Juliya Kalinina, Merck & Co., USA
Short Talk: Highly Sensitive and Selective Amyloid Oligomer Biomarker Assay Differentiates Alzheimer’s from Non-AD Cerebrospinal Fluid (CSF) and Tissues

Tuesday, March 04 | 8:00AM - 11:15AM
Biomarkers of AD and PD (Joint)
Room: Longs/Grays Peaks

Speaker 6 of 7
Thomas J. Montine, University of Washington Medical Center, USA
Modifiable Factors Associated with Free Radical Injury in the Aging Brain

Tuesday, March 04 | 8:00AM - 11:15AM
Biomarkers of AD and PD (Joint)
Room: Longs/Grays Peaks

Speaker 7 of 7
Alice S. Chen-Plotkin, University of Pennsylvania School of Medicine, USA
Unbiased Approaches to Parkinson's Disease Biomarker Discovery

Tuesday, March 04 | 9:20AM - 9:40AM
Coffee Break
Room: Longs Peak Foyer


Tuesday, March 04 | 11:15AM - 12:45PM
Future Opportunities and Obstacles in PD Research
This session is from Parkinson's Disease
Room: Grays Peak
Jamie Eberling of the Michael J. Fox Foundation will host a short forum bringing together PD researchers and some of the funding bodies to discuss future opportunities and obstacles in PD research, and how the research and funding community can work together to take advantage/overcome these obstacles.


Tuesday, March 04 | 11:15AM - 1:00PM
Poster Setup
Room: Quandary Peak


Tuesday, March 04 | 11:15AM - 2:30PM
On Own for Lunch and Recreation


Tuesday, March 04 | 1:00PM - 10:00PM
Poster Viewing
Room: Quandary Peak


Tuesday, March 04 | 2:30PM - 4:30PM
Panel: Combo Therapy for AD
Room: Longs Peak

Speaker 1 of 5
* Dennis J. Selkoe, Harvard Medical School, USA

Tuesday, March 04 | 2:30PM - 4:30PM
Panel: Combo Therapy for AD
Room: Longs Peak

Speaker 2 of 5
Ryan J. Watts, Denali Therapeutics Inc, USA

Tuesday, March 04 | 2:30PM - 4:30PM
Panel: Combo Therapy for AD
Room: Longs Peak

Speaker 3 of 5
Charles F. Albright, Editas Medicine, USA

Tuesday, March 04 | 2:30PM - 4:30PM
Panel: Combo Therapy for AD
Room: Longs Peak

Speaker 4 of 5
Michael K. Ahlijanian, Bristol-Myers Squibb, USA
Pros and Cons of Combo Therapy from a Biopharma Drug Discovery and Development Perspective

Tuesday, March 04 | 2:30PM - 4:30PM
Panel: Combo Therapy for AD
Room: Longs Peak

Speaker 5 of 5
Reisa A. Sperling, Brigham and Women's Hospital, Harvard Medical School, USA
Pros and Cons of Combo Therapy from a Clinical Researcher and the Patient's Perspective

Tuesday, March 04 | 4:00PM - 4:30PM
Coffee Available
Room: Longs Peak Foyer


Tuesday, March 04 | 4:30PM - 6:30PM
AD Biomarkers
Room: Longs Peak

Speaker 1 of 5
* Thomas J. Montine, University of Washington Medical Center, USA

Tuesday, March 04 | 4:30PM - 6:30PM
AD Biomarkers
Room: Longs Peak

Speaker 2 of 5
Daniel M. Skovronsky, Eli Lilly and Company, USA
Amyloid Imaging

Tuesday, March 04 | 4:30PM - 6:30PM
AD Biomarkers
Room: Longs Peak

Speaker 3 of 5
David M. Holtzman, Washington University, USA
Sleep and Circadian Rhythms: Potential Bidirectional Relationship with Alzheimer’s Disease

Tuesday, March 04 | 4:30PM - 6:30PM
AD Biomarkers
Room: Longs Peak

Speaker 4 of 5
Clifford R. Jack, Mayo Clinic, USA
Alzheimer’s Disease Biomarkers

Tuesday, March 04 | 4:30PM - 6:30PM
AD Biomarkers
Room: Longs Peak

Speaker 5 of 5
Wendy Wei Qiao Qiu, Boston University School of Medicine, USA
Short Talk: Amylin and its Analog: Potential Diagnostic Test and Therapeutic Drug for Alzheimer’s Disease

Tuesday, March 04 | 4:30PM - 6:30PM
Mitochondrial Biology and the Pathology of PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 1 of 5
* Mark R. Cookson, NIA, National Institutes of Health, USA


Tuesday, March 04 | 4:30PM - 6:30PM
Mitochondrial Biology and the Pathology of PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 2 of 5
Richard J. Youle, NINDS, National Institutes of Health, USA
Role of PINK1 and Parkin on Mitochondria Quality Control in vitro and in vivo


Tuesday, March 04 | 4:30PM - 6:30PM
Mitochondrial Biology and the Pathology of PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 3 of 5
Helene Marie Plun-Favreau, University College London Institute of Neurology, UK
Missing Pieces in the Mitophagy Puzzle


Tuesday, March 04 | 4:30PM - 6:30PM
Mitochondrial Biology and the Pathology of PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 4 of 5
J. Wade Harper, Harvard Medical School / Biogen Idec, USA
Short Talk: Parkin-Dependent Ubiquitin Chain Synthesis in vivo and in vitro


Tuesday, March 04 | 4:30PM - 6:30PM
Mitochondrial Biology and the Pathology of PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 5 of 5
Alex J. Whitworth, University of Sheffield, UK
Drosophila Models of Parkinson's Disease


Tuesday, March 04 | 6:30PM - 7:30PM
Social Hour with Lite Bites
Room: Quandary Peak


Tuesday, March 04 | 7:30PM - 10:00PM
Poster Session 2
Room: Quandary Peak


Wednesday, March 05 | 7:00AM - 8:00AM
Breakfast
Room: Quandary Peak


Wednesday, March 05 | 8:00AM - 11:15AM
What Are the Toxic Species of Tau, Abeta and alpha-Synuclein
(Joint)

Room: Longs/Grays Peaks

Speaker 1 of 6
Karen Hsiao Ashe, University of Minnesota, USA
Relevance of Quaternary Structure to the Functional Effects of beta-Amyloid Oligomers in the Brain

Wednesday, March 05 | 8:00AM - 11:15AM
What Are the Toxic Species of Tau, Abeta and alpha-Synuclein
(Joint)

Room: Longs/Grays Peaks

Speaker 2 of 6
Dennis J. Selkoe, Harvard Medical School, USA
Protein Misfolding in AD and PD: New Mechanistic Insights

Wednesday, March 05 | 8:00AM - 11:15AM
What Are the Toxic Species of Tau, Abeta and alpha-Synuclein
(Joint)

Room: Longs/Grays Peaks

Speaker 3 of 6
Danielle Mor, University of Pennsylvania, USA
Short Talk: The Role of Dopamine in Generating Toxic Oligomeric Conformers of Alpha-Synuclein

Wednesday, March 05 | 8:00AM - 11:15AM
What Are the Toxic Species of Tau, Abeta and alpha-Synuclein
(Joint)

Room: Longs/Grays Peaks

Speaker 4 of 6
Vincent Raussens, Université Libre de Bruxelles, Belgium
Short Talk: Unraveling the Interaction between apoE and Amyloid beta Peptide Using Crosslinking and Mass Spectrometry

Wednesday, March 05 | 8:00AM - 11:15AM
What Are the Toxic Species of Tau, Abeta and alpha-Synuclein
(Joint)

Room: Longs/Grays Peaks

Speaker 5 of 6
Vikram Khurana, Whitehead Institute for Biomedical Research and Massachusetts General Hospital, USA
A-Synuclein Toxicity: Phenotypic Screen from Yeast to Patient iPSc Cells

Wednesday, March 05 | 8:00AM - 11:15AM
What Are the Toxic Species of Tau, Abeta and alpha-Synuclein
(Joint)

Room: Longs/Grays Peaks

Speaker 6 of 6
* Hui Zheng, Baylor College of Medicine, USA
Clearance of Toxic Tau Proteins and Rescue of Neurotoxicity by TFEB

Wednesday, March 05 | 9:20AM - 9:40AM
Coffee Break
Room: Longs Peak Foyer


Wednesday, March 05 | 11:15AM - 12:45PM
NIH Panel (Joint): New AD and PD Recommendations
Room: Longs/Grays Peaks

Speaker 1 of 3
Creighton Tony Phelps, NIA, National Institutes of Health, USA

Wednesday, March 05 | 11:15AM - 12:45PM
NIH Panel (Joint): New AD and PD Recommendations
Room: Longs/Grays Peaks

Speaker 2 of 3
Thomas J. Montine, University of Washington Medical Center, USA

Wednesday, March 05 | 11:15AM - 12:45PM
NIH Panel (Joint): New AD and PD Recommendations
Room: Longs/Grays Peaks

Speaker 3 of 3
Beth-Anne Sieber, NINDS, National Institutes of Health, USA

Wednesday, March 05 | 11:15AM - 1:00PM
Poster Setup
Room: Quandary Peak


Wednesday, March 05 | 12:45PM - 4:30PM
On Own for Lunch and Recreation


Wednesday, March 05 | 1:00PM - 10:00PM
Poster Viewing
Room: Quandary Peak


Wednesday, March 05 | 4:00PM - 4:30PM
Coffee Available
Room: Longs Peak Foyer


Wednesday, March 05 | 4:30PM - 6:30PM
Transmission of Tau and Abeta
Room: Longs Peak

Speaker 1 of 5
* Michael K. Ahlijanian, Bristol-Myers Squibb, USA

Wednesday, March 05 | 4:30PM - 6:30PM
Transmission of Tau and Abeta
Room: Longs Peak

Speaker 2 of 5
John Q. Trojanowski, University of Pennsylvania, USA
Transmission of Tau Pathology: A New Model for the Progression of Tauopathies

Wednesday, March 05 | 4:30PM - 6:30PM
Transmission of Tau and Abeta
Room: Longs Peak

Speaker 3 of 5
Virginia M. Y. Lee, University of Pennsylvania School of Medicine, USA
Transmission of alpha-Synculein in Parkinson’s Disease

Wednesday, March 05 | 4:30PM - 6:30PM
Transmission of Tau and Abeta
Room: Longs Peak

Speaker 4 of 5
Zeshan Ahmed, Eli Lilly and Company, UK
Short Talk: A Novel in vivo Model of Tau Propagation that Is Suitable for Evaluating the Efficacy of Tau-Based Therapeutic Strategies

Wednesday, March 05 | 4:30PM - 6:30PM
Transmission of Tau and Abeta
Room: Longs Peak

Speaker 5 of 5
Karen Duff, Columbia University, USA
Propagation of Pathology and Functional Decline in AD

Wednesday, March 05 | 4:30PM - 6:30PM
Pluripotent Stem Cells and Inherited PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 1 of 5
* Patrick A. Lewis, University of Reading, UK


Wednesday, March 05 | 4:30PM - 6:30PM
Pluripotent Stem Cells and Inherited PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 2 of 5
Tilo Kunath, University of Edinburgh, UK
Alpha-Synuclein Dysfunction in Pluripotent Stem Cell Derived Neurons


Wednesday, March 05 | 4:30PM - 6:30PM
Pluripotent Stem Cells and Inherited PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 3 of 5
Dimitri Krainc, Northwestern University, USA
Links between Lysosomal Dysfunction and Neurodegeneration


Wednesday, March 05 | 4:30PM - 6:30PM
Pluripotent Stem Cells and Inherited PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 4 of 5
Birgitt Schuele, Stanford University, USA
Short Talk: Mitochondrial Dysfunction in Patient-Derived LRRK2 Stem Cell Models


Wednesday, March 05 | 4:30PM - 6:30PM
Pluripotent Stem Cells and Inherited PD
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 5 of 5
Jared Sterneckert, Max-Planck-Institut für Molekulare Biomedizin, Germany
Modeling Parkinson’s Disease Induced by Mutant LRRK2 Using Isogenic Human iPSCs


Wednesday, March 05 | 6:30PM - 7:30PM
Social Hour with Lite Bites
Room: Quandary Peak


Wednesday, March 05 | 7:30PM - 10:00PM
Poster Session 3
Room: Quandary Peak


Thursday, March 06 | 7:00AM - 8:00AM
Breakfast
Room: Quandary Peak


Thursday, March 06 | 8:00AM - 11:15AM
Passive Immunization and Other Novel Therapies to Treat AD a
nd PD (Joint)

Room: Longs/Grays Peaks

Speaker 1 of 7
* Ryan J. Watts, Denali Therapeutics Inc, USA

Thursday, March 06 | 8:00AM - 11:15AM
Passive Immunization and Other Novel Therapies to Treat AD a
nd PD (Joint)

Room: Longs/Grays Peaks

Speaker 2 of 7
Eliezer Masliah, University of California, San Diego, USA
Passive Immunization Therapies for Parkinson’s Disease

Thursday, March 06 | 8:00AM - 11:15AM
Passive Immunization and Other Novel Therapies to Treat AD a
nd PD (Joint)

Room: Longs/Grays Peaks

Speaker 3 of 7
Kurt R. Brunden, University of Pennsylvania, USA
Microtubule Stabilizing Drugs to Treat Axonal Transport Failure in AD and PD

Thursday, March 06 | 8:00AM - 11:15AM
Passive Immunization and Other Novel Therapies to Treat AD a
nd PD (Joint)

Room: Longs/Grays Peaks

Speaker 4 of 7
Zdenek Berger, Pfizer, USA
Short Talk: Effects of Tool Compounds on Glucocerebrosidase Activity in Human and Mouse Brain Lysates

Thursday, March 06 | 8:00AM - 11:15AM
Passive Immunization and Other Novel Therapies to Treat AD a
nd PD (Joint)

Room: Longs/Grays Peaks

Speaker 5 of 7
Eva Czirr, Alkahest, USA
Short Talk: Complement Receptor 3 Deficiency Reduces Alzheimer’s Disease Amyloid Pathology in Mice

Thursday, March 06 | 8:00AM - 11:15AM
Passive Immunization and Other Novel Therapies to Treat AD a
nd PD (Joint)

Room: Longs/Grays Peaks

Speaker 6 of 7
Marc Mercken, Janssen R&D, Belgium
Translating Alzheimer’s Disease Science into Breakthrough Therapies

Thursday, March 06 | 8:00AM - 11:15AM
Passive Immunization and Other Novel Therapies to Treat AD a
nd PD (Joint)

Room: Longs/Grays Peaks

Speaker 7 of 7
Michael K. Ahlijanian, Bristol-Myers Squibb, USA
Challenges Facing the Development of Disease Modifying Therapies for Alzheimer’s Disease

Thursday, March 06 | 9:20AM - 9:40AM
Coffee Break
Room: Longs Peak Foyer


Thursday, March 06 | 11:15AM - 4:30PM
On Own for Lunch and Recreation


Thursday, March 06 | 4:00PM - 4:30PM
Coffee Available
Room: Longs Peak Foyer


Thursday, March 06 | 4:30PM - 6:30PM
AD Prevention versus Intervention Trials
Room: Longs Peak

Speaker 1 of 4
Reisa A. Sperling, Brigham and Women's Hospital, Harvard Medical School, USA
Secondary Prevention Trials in Preclinical Alzheimer’s Disease

Thursday, March 06 | 4:30PM - 6:30PM
AD Prevention versus Intervention Trials
Room: Longs Peak

Speaker 2 of 4
Leonard Petrucelli, Mayo Clinic Jacksonville, USA
Short Talk: HDAC6 Inhibition as a Treatment of Tauopathies

Thursday, March 06 | 4:30PM - 6:30PM
AD Prevention versus Intervention Trials
Room: Longs Peak

Speaker 3 of 4
Mark S. Forman, Merck, USA
BACE1 Inhibitors for Alzheimer’s Disease

Thursday, March 06 | 4:30PM - 6:30PM
AD Prevention versus Intervention Trials
Room: Longs Peak

Speaker 4 of 4
* John Q. Trojanowski, University of Pennsylvania, USA
Concluding Remarks

Thursday, March 06 | 4:30PM - 6:30PM
LRRK2 Biology and PD Therapeutics
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 1 of 5
* Marcel P. van der Brug, Genentech, Inc., USA


Thursday, March 06 | 4:30PM - 6:30PM
LRRK2 Biology and PD Therapeutics
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 2 of 5
Mark R. Cookson, NIA, National Institutes of Health, USA
A State-of-the-Protein View of LRKK2


Thursday, March 06 | 4:30PM - 6:30PM
LRRK2 Biology and PD Therapeutics
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 3 of 5
Anthony A. Estrada, Genentech, Inc., USA
Discovery of LRRK2 Small Molecule Inhibitors for the Treatment of PD


Thursday, March 06 | 4:30PM - 6:30PM
LRRK2 Biology and PD Therapeutics
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 4 of 5
Warren D. Hirst, Pfizer Neuroscience Research Unit, USA
Short Talk: Development of Assays to Measure LRRK2 Levels and Activity in Sporadic Parkinson’s Disease Brain


Thursday, March 06 | 4:30PM - 6:30PM
LRRK2 Biology and PD Therapeutics
This session is from Parkinson's Disease
Room: Grays Peak

Speaker 5 of 5
Arjan Kortholt, University of Groningen, Netherlands
Structural Studies on Roco Proteins and Implications for LRRK2


Thursday, March 06 | 6:30PM - 7:30PM
Social Hour with Lite Bites
Room: Quandary Peak


Thursday, March 06 | 7:30PM - 10:30PM
Entertainment
Room: Quandary Peak


Thursday, March 06 | 7:30PM - 10:30PM
Cash Bar
Room: Quandary Peak


Friday, March 07 | 10:23AM - 10:23AM
Departure


*Session Chair
†Invited, not yet responded.